Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • A record month for Medlab has seen shares rise as more and more patients take up its medicinal cannabis spray medication
  • Medlab sold 846 bottles of its NanaBis and NanaBidial products last month, bring in record revenues over October
  • Three patient studies also showed strong pain relief and anti-depression results
  • Today’s strong run of shares marks the end of a steady decline seen over the past month
  • Medlab shares are up 13.24 per cent at mid-afternoon trade worth 38 cents each

A record month for Medlab has seen a share price spike, perhaps marking the end of a steady decline of shares over November.

At the start of the month, Medlab responded to an Australian Securities Exchange (ASX)-issued query regarding its most recent quarterly report where it said it expects continued negative cash flows for the time being.

Today, however, the medical company reported a record month for sales of its medicinal cannabis bottles NanaBis and NanaBidial, with 846 bottles sold over October.

This brought about a record month of revenue for Medlab.

Both NanaBis and NanaBidial are cannabis-oil sprays designed to treat pain, depression, and obesity. They use Medlab’s NanoCelle delivery platform and can be applied by spraying on a patient’s cheeks.

As part of the announcement, Medlab revealed the results of three different patient studies from three different doctors for the NanaBis product.

Two of the patients took the medication for pain associated cancer with some strong results. One patient’s pain score reduced from a nine-out-of-ten to a two-out-of-ten, with an increased appetite and improved sleep. The other patient reported no pain at all and was able to walk freely without crutches after using NanaBis.

The third patient suffered neuropathic pain but reported better sleep, reduced pain, and reduced social anxiety after being prescribed NanaBis.

Today’s announcement, however, was not part of a quarterly or half-year report, suggesting perhaps Medlab was just excited about the news or the company is trying to instil some confidence in investors following the company’s slow share price decline.

Regardless of the intent, the news seems to have satisfied the market, as Medlab shares are up 13.24 per cent at mid-afternoon trade. Shares are currently worth 38 cents each in an $82.92 million market cap.

MDC by the numbers
More From The Market Herald
Dimerix (ASX:DXB) - Managing Director and CEO, Nina Webster

" Dimerix (ASX:DXB) expands DMX-200 study into Australia

Dimerix (DXB) has entered an agreement with the NHMRC Clinical Trials Centre at the University of Sydney to expand the CLARITY 2.

" ACCC scrambles to halt Virtus Health’s (ASX:VRT) purchase of Healius (ASX:HLS) IVF clinics

The ACCC has taken “a significant step” as it seeks an urgent injunction to stop Virtus Health’s (VRT) proposed acquisition of Adora Fertility
IDT Australia (ASX:IDT) - Chair, Alan Fisher

" IDT Australia (ASX:IDT) signs manufacturing deal with Monash University

IDT Australia (IDT) has entered a master services agreement and services order with Monash University.
Prescient Therapeutics (PTX) - CEO and MD, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) to present new OmniCAR data at conference

Prescient Therapeutics (PTX) will present new results for its OmniCAR drug at the Cell & Gene Meeting on Mesa in California.